metabolic associated fatty liver disease
Conditions
Interventions
1:On the basis of basic treatment patients were given conventional Western medicine either Silymarin Capsules (Lijialong) (140mg*10 capsules per box) with the administration method of 3 times a day 1
or Polyene Phosphatidylcholine Capsules (Eshanfu) (228mg*24 capsules per box) with the administration method of 3 times a day 1 capsule each time orally
the medication duration was no less than 12 weeks.
2:Based on primary therapy, regularly take Shugan Huoxue Tiaozhi Decoction (YuZhizi 9g, Zhuru 9g, ShuiHonghuazi 9g, Taoren 9g, Heye 15g, ZhiDahuang 6g, ZhiGancao 6g, Jiaogulan 18g). Modifications: add
Huangqin 6-9g/Huanglian 3g/Huzhang 9-15g for damp-heat
Yujin 6-9g/Chuanxiong 6-9g/Yanhusuo 6-9g for blood stasis. Herbs provided by Shuguang Hospital. Decoction: 1 dose daily (twice) for =12 weeks.
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
10 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria of MAFLD 2) Conform to the TCM syndrome differentiation standard of liver Ganyu Xueyu syndrome 3) The medical records of western medicine were relatively complete and the clinical symptoms treatment methods and auxiliary examinations were recorded in the medical records. 4)The TCM medical records contained detailed information of the four diagnoses treatment principles and methods and relevant records of TCM prescriptions. 5) The time from the first visit to the last follow-up medical records was not less than 3 months and the follow-up medical records were relatively complete.
Exclusion criteria
Exclusion criteria: 1) Patients with serious lack of medical history and clinical data and unable to follow up or trace through various ways; 2) those who did not regularly take the Shugan Huoxue Tiaozhi decoction during the treatment period; 3) patients with a history of chronic viral hepatitis drug-induced liver disease or other serious liver and kidney dysfunction; 4) taking other traditional Chinese medicine during the treatment cycle; 5) pregnant or lactating women; 6) patients with serious heart liver kidney brain and other diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome score;liver function;FibroScan;Liver ultrasound; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic fibrosis-4 index score;blood fat; | — |
Countries
China
Contacts
Public ContactChengyang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed